T1	Participants 750 841	patients with tuberous sclerosis complex who had SEGA that was growing and needed treatment
T2	Participants 880 1128	all patients who had been assigned everolimus during the double-blind, randomised phase of the trial and those patients who crossed over from the placebo group to receive everolimus during the randomised phase or at the start of the extension phase
T3	Participants 1705 1744	original 117 randomly assigned patients
